ARTICLE | Company News
LivTech, Yakult deal
November 14, 2011 8:00 AM UTC
Yakult received an option to license exclusive, worldwide rights to develop and commercialize LivTech's preclinical LIV-2008 humanized mAb cancer program. The companies will jointly conduct preclinica...